Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Intervalo de año de publicación
1.
Braz. j. med. biol. res ; 44(2): 100-104, Feb. 2011. ilus, tab
Artículo en Inglés | LILACS | ID: lil-573652

RESUMEN

The objective of this study was to determine the levels of TERT mRNA and TERT protein expression in stomach precancerous lesions such as intestinal metaplasia (IM) and gastric ulcer (GU) and compare them to gastric cancer (GC). Real-time PCR was performed to detect TERT mRNA expression levels in 35 biopsies of IM, 30 of GU, and 22 of GC and their respective normal mucosas. TERT protein was detected by immunohistochemistry in 68 samples, 34 of IM, 23 of GU, and 11 of GC. Increased TERT mRNA expression levels were observed in a significant number of cases, i.e., 46 percent of IM, 50 percent of GU, and 79 percent of GC. The relative mean level of TERT mRNA after normalization with the β-actin reference gene and comparison with the respective adjacent normal mucosa was slightly increased in the IM and GU groups, 2.008 ± 2.605 and 2.730 ± 4.120, respectively, but high TERT mRNA expression was observed in the GC group (17.271 ± 33.852). However, there were no statistically significant differences between the three groups. TERT protein-positive immunostaining was observed in 38 percent of IM, 39 percent of GU, and 55 percent of GC. No association of TERT mRNA and protein expression with Helicobacter pylori infection or other clinicopathological variables was demonstrable, except for the incomplete type vs the complete type of IM. This study confirms previous data of the high expression of both TERT mRNA and protein in gastric cancer and also demonstrates this type of changed expression in IM and GU, thus suggesting that TERT expression may be deregulated in precursor lesions that participate in the early stages of gastric carcinogenesis.


Asunto(s)
Humanos , Persona de Mediana Edad , Lesiones Precancerosas/metabolismo , ARN Mensajero/análisis , Neoplasias Gástricas/metabolismo , Úlcera Gástrica/metabolismo , Telomerasa/análisis , Adenocarcinoma/metabolismo , Adenocarcinoma/patología , Helicobacter pylori , Infecciones por Helicobacter/metabolismo , Infecciones por Helicobacter/patología , Inmunohistoquímica , Intestinos/patología , Metaplasia/metabolismo , Proteínas de Neoplasias/metabolismo , Lesiones Precancerosas/patología , Reacción en Cadena en Tiempo Real de la Polimerasa , Neoplasias Gástricas/patología , Úlcera Gástrica/patología , Telomerasa/genética
2.
Braz J Med Biol Res ; 44(2): 100-4, 2011 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-21180888

RESUMEN

The objective of this study was to determine the levels of TERT mRNA and TERT protein expression in stomach precancerous lesions such as intestinal metaplasia (IM) and gastric ulcer (GU) and compare them to gastric cancer (GC). Real-time PCR was performed to detect TERT mRNA expression levels in 35 biopsies of IM, 30 of GU, and 22 of GC and their respective normal mucosas. TERT protein was detected by immunohistochemistry in 68 samples, 34 of IM, 23 of GU, and 11 of GC. Increased TERT mRNA expression levels were observed in a significant number of cases, i.e., 46% of IM, 50% of GU, and 79% of GC. The relative mean level of TERT mRNA after normalization with the ß-actin reference gene and comparison with the respective adjacent normal mucosa was slightly increased in the IM and GU groups, 2.008 ± 2.605 and 2.730 ± 4.120, respectively, but high TERT mRNA expression was observed in the GC group (17.271 ± 33.852). However, there were no statistically significant differences between the three groups. TERT protein-positive immunostaining was observed in 38% of IM, 39% of GU, and 55% of GC. No association of TERT mRNA and protein expression with Helicobacter pylori infection or other clinicopathological variables was demonstrable, except for the incomplete type vs the complete type of IM. This study confirms previous data of the high expression of both TERT mRNA and protein in gastric cancer and also demonstrates this type of changed expression in IM and GU, thus suggesting that TERT expression may be deregulated in precursor lesions that participate in the early stages of gastric carcinogenesis.


Asunto(s)
Lesiones Precancerosas/metabolismo , ARN Mensajero/análisis , Neoplasias Gástricas/metabolismo , Úlcera Gástrica/metabolismo , Telomerasa/análisis , Adenocarcinoma/metabolismo , Adenocarcinoma/patología , Infecciones por Helicobacter/metabolismo , Infecciones por Helicobacter/patología , Helicobacter pylori , Humanos , Inmunohistoquímica , Intestinos/patología , Metaplasia/metabolismo , Persona de Mediana Edad , Proteínas de Neoplasias/metabolismo , Lesiones Precancerosas/patología , Reacción en Cadena en Tiempo Real de la Polimerasa , Neoplasias Gástricas/patología , Úlcera Gástrica/patología , Telomerasa/genética
3.
Crit Care Med ; 28(10): 3396-404, 2000 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11057792

RESUMEN

OBJECTIVE: To evaluate the effects of maximizing the oxygen delivery on morbidity and mortality in patients >60 yrs of age and/or with chronic diseases of vital organs who underwent major elective surgery. DESIGN: Prospective, randomized, controlled trial. SETTING: A 24-bed general intensive care unit of a teaching hospital. PATIENTS: Thirty-seven high-risk patients who underwent major surgery. INTERVENTIONS: The hemodynamic and oxygen transport variables and outcomes in 18 patients (control group) treated to maintain normal values of oxygen delivery were compared with 19 patients (protocol group) treated to maintain "supranormal" values. Therapy in both groups consisted of volume expansion and, when necessary, dobutamine to reach target values, during the surgery and 24 hrs postoperatively. MEASUREMENTS AND MAIN RESULTS: We interrupted the study because of a significant difference in the 60-day mortality rate. The mortality rate in the control group was significantly higher when compared with the protocol group (9/18 [50%] vs. 3/19 [15.7%], p < .05). The prevalence of clinical and infectious complications was higher in the control group than in the protocol group (67% and 31% respectively; relative risk, 0.47; 95% confidence interval, 0.226-0.991; p < .05) and there was a trend toward more severe organ dysfunction in nonachievers patients (17/24 [71%] vs. 6/13 [46%], relative risk, 0.65; 95% confidence interval, 0.343-1.237; NS). CONCLUSION: Older patients with existing cardiorespiratory illness undergoing major surgery have a reduced morbidity and mortality when dobutamine is used to maximize oxygen transport.


Asunto(s)
Cardiotónicos/uso terapéutico , Dobutamina/uso terapéutico , Procedimientos Quirúrgicos Electivos/efectos adversos , Procedimientos Quirúrgicos Electivos/mortalidad , Hemodinámica/efectos de los fármacos , Consumo de Oxígeno/efectos de los fármacos , Anciano , Anciano de 80 o más Años , Enfermedad Crónica , Humanos , Cuidados Intraoperatorios/métodos , Persona de Mediana Edad , Morbilidad , Insuficiencia Multiorgánica/etiología , Cuidados Posoperatorios/métodos , Estudios Prospectivos , Análisis de Supervivencia , Factores de Tiempo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA